Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma

NCT04514393 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Primary Central Nervous System Lymphoma
PCNSL
Non Hodgkin Lymphoma

Interventions

DRUG: Methotrexate
DRUG: Ibrutinib
DRUG: Temozolomide

Sponsor

Huiqiang Huang

Collaborators

[object Object]
[object Object]
[object Object]